Identifying RAGE inhibitors as potential therapeutics for Alzheimer's disease via integrated in-silico approaches.

ABSTRACT: Alzheimer's disease is a neurodegenerative disorder characterized by two hallmarks: amyloid beta plaques and neurofibrillary tangles. The receptor for advanced glycation end products (RAGE) is a multi-ligand receptor involved in the pathophysiology of various diseases including cancer, diabetes, cardiovascular diseases, and Alzheimer's disease (AD). Therefore, targeting RAGE could be an effective strategy to block RAGE signaling pathways. The present study aims to identify potential RAGE inhibitors against AD through comprehensive in-silico approaches. A total of 708,580 compounds were screened from numerous databases using structure-based virtual screening and ADMET evaluation. Further, the molecules with good glide scores were assessed by molecular docking studies. Subsequently, the top

SUBMITTER: Bhogal I 

PROVIDER: S-EPMC12098779 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature